Patents by Inventor Laura Standaert

Laura Standaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of NEAT1 for treatment of solid tumors
    Patent number: 9783803
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: October 10, 2017
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert
  • INHIBITION OF NEAT1 FOR TREATMENT OF SOLID TUMORS
    Publication number: 20170009229
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Application
    Filed: February 9, 2015
    Publication date: January 12, 2017
    Inventors: Jean-Christophe Marine, Laura Standaert
  • Inhibition of NEAT1 for treatment of solid tumors
    Patent number: RE48856
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert